Disease risk estimates in V30M variant transthyretin amyloidosis (A-ATTRv) from Mallorca

por Cisneros-Barroso, E., Gorram, F., Ribot-Sansó, M. A., Alarcon, F., Nuel, G., González-Moreno, J., Rodríguez, A., Hernandez-Rodriguez, J., Amengual-Cladera, E., Martínez-López, I., Ripoll-Vera, T., Losada-López, I., Heine-Suñer, D., Plante-Bordeneuve, V.
Publicado 2023

Early data on long‐term efficacy and safety of inotersen in patients with hereditary transthyretin amyloidosis: a 2‐year update from the open‐label extension of the NEURO‐TTR trial...

por Brannagan, T. H., Wang, A. K., Coelho, T., Waddington Cruz, M., Polydefkis, M. J., Dyck, P. J., Plante‐Bordeneuve, V., Berk, J. L., Barroso, F., Merlini, G., Conceição, I., Hughes, S. G., Kwoh, J., Jung, S. W., Guthrie, S., Pollock, M., Benson, M. D., Gertz, M.
Publicado 2020